Wave Life Sciences Ltd 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Wave Life Sciences Ltd 's ROA in the third quarter of 2026?
Wave Life Sciences Ltd recorded a cumulative net loss of $-211 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -34.94%.

However, within the Healthcare sector 468 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3826, from total ROA ranking in the second quarter of 2026 at 4678.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	108.75 %	168.28 %	103.7 %	91 %	-29.25 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-211	-202	-176	-197	-114
Return On Assets (TTM)	-34.94 %	-37.7 %	-40.78 %	-55.18 %	-40.8 %
WVE's Total Ranking	# 3826	# 4678	# 3930	# 3951	# 4000
Total Assets (TTM) in million	504	677	587	642	241
Seq. Total Assets Change	-25.58 %	15.26 %	-8.55 %	166.1 %	-4.35 %
Seq. Net Income Change	-	-	-	-	-

WVE's 5 Years Annual ROA >> Back to WVE Management Effectiveness >> Compare WVE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 185
Sector	# 469
Overall	# 3735

Return On Assets Statistics
High	Average	Low
-21.49 %	-48.8 %	-91.35 %
(Jun 30 2016)		(Dec 31 2022)

Financial Statements
Wave Life Sciences Ltd 's Assets	$ 504 million	WVE's Balance sheet
Wave Life Sciences Ltd 's Income	$ -62 million	Quarterly WVE's Income Statement
WVE's Income by Division		See WVE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	91 %	32.84 %	108.39 %	-36.22 %	-27.82 %
Total Assets in million	642	336	253	121	190
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-204	-97	-58	-162	-122
Annual Return On Assets	-31.82 %	-28.85 %	-22.72 %	-133.21 %	-64.18 %

WVE's 5 Years Annual ROA >> Back to WVE Management Effectiveness >> Compare WVE ROA to its Competitors

More Return On Assets Ratios
WVE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
WVE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for WVE's Competitors
Subscribers only: Roa for Wave Life Sciences Ltd 's Suppliers
Subscribers only: Return On Assets for WVE's Customers

You may also want to know
WVE's Roi	WVE's Inventory Turnover Ratio	WVE's Growth Rates	WVE's Dividend Comparisons
	WVE's Profitability Ratios	WVE's Asset Turnover Ratio	WVE's Dividend Growth
WVE's Roe	WVE's Valuation Ratios	WVE's Financial Strength Ratios	WVE's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-10-28T09:29:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.